Primary Cholangitis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for primary cholangitis. 14 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
14
Active US patents
24/100
Avg vulnerability
—
Annual revenue covered

Originators in Primary Cholangitis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Intercept Pharms Inc 14 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating primary cholangitis. Each bar = one year. Y-axis scaled to peak year (6 patents).

2
27
6
33
6
36

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Ocaliva
OBETICHOLIC ACID
 Intercept Pharms Inc 14 24 — 2027-02-21

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10047117 Ocaliva method of use 45 2033-09-06
10047117 Ocaliva method of use 45 2033-09-06
10758549 Ocaliva method of use 45 2036-04-26
10758549 Ocaliva method of use 45 2036-04-26
9238673 Ocaliva formulation 25 2033-06-17
9238673 Ocaliva formulation 25 2033-06-17
10052337 Ocaliva formulation 25 2036-04-26
10751349 Ocaliva formulation 25 2036-04-26
10751349 Ocaliva formulation 25 2036-04-26
10052337 Ocaliva formulation 25 2036-04-26

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10174073 Ocaliva composition of matter 0 2033-06-17
10174073 Ocaliva composition of matter 0 2033-06-17
RE48286 Ocaliva composition of matter 5 2027-02-21
RE48286 Ocaliva composition of matter 5 2027-02-21
10052337 Ocaliva formulation 25 2036-04-26
10751349 Ocaliva formulation 25 2036-04-26
10052337 Ocaliva formulation 25 2036-04-26
10751349 Ocaliva formulation 25 2036-04-26
9238673 Ocaliva formulation 25 2033-06-17
9238673 Ocaliva formulation 25 2033-06-17

Related